Armata Pharmaceuticals (ARMP) Return on Capital Employed (2014 - 2026)

Armata Pharmaceuticals has disclosed Return on Capital Employed across 13 years of filings, most recently posting 58.07% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 58.07%, down 22856.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 58.07% (down 22856.0% YoY), and the FY2025 annual result was 50.38%, up 4573.0% from the prior year.
• Return on Capital Employed came in at 58.07% for Q1 2026 at Armata Pharmaceuticals, down from 49.34% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 5801.9% in Q1 2024 to a low of 96.26% in Q4 2024.
• The 5-year median for Return on Capital Employed is 36.32% (2022), against an average of 369.42%.
• Across the five-year window, Return on Capital Employed jumped 587955 bps in 2024 and slumped 563141 bps in 2025, its largest moves.
• Armata Pharmaceuticals' Return on Capital Employed stood at 53.17% in 2022, then rose by 14 bps to 45.89% in 2023, then plunged by 110 bps to 96.26% in 2024, then surged by 49 bps to 49.34% in 2025, then dropped by 18 bps to 58.07% in 2026.
• The last three Return on Capital Employed figures came in at 58.07% (Q1 2026), 49.34% (Q4 2025), and 60.86% (Q3 2025), per Business Quant data.